MCM
MCRB icon

Mazama Capital Management’s Seres Therapeutics MCRB Stock Holding History

Mazama Capital Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-29
Closed -$24K – 298
2015
Q2 		$24K Buy
+29
New +$25.3K ﹤0.01% 249

Other funds holding MCRB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 39.77% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Mazama Capital Management's MCRB Position: Q3 2015 in Review

Mazama Capital Management sold out of Seres Therapeutics (MCRB) in Q3 2015, closing a stake of 29 shares — an estimated $24K sold.

Mazama Capital Management first reported a position in MCRB in Q2 2015 and held it in 1 quarter. The position peaked at $24K in Q2 2015. 60 funds tracked by Wall St. Rank hold MCRB as of Q3 2015.

  • Mazama Capital Management reported no remaining Seres Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Mazama Capital Management sold 29 Seres Therapeutics shares in Q3 2015, an estimated $24K.
  • Mazama Capital Management first reported a position in Seres Therapeutics in Q2 2015 and held it in 1 quarter.
  • Mazama Capital Management's Seres Therapeutics position peaked at $24K in Q2 2015.
  • 60 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2015.

Based on Mazama Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.